On February 4, 2022 Privo Technologies, Inc. ("Privo"), a clinical-stage biopharmaceutical company focused on optimizing state-of-the-art chemotherapies to be "Tough on cancer, Easy on patients", reported that it will give a virtual company presentation and participate in one-on-one investor meetings at the 2022 BIO CEO & Investor Conference from February 14-17 (Press release, Privo Technologies, FEB 4, 2022, View Source;utm_medium=rss&utm_campaign=privo-technologies-inc-to-present-at-the-24th-annual-bio-ceo-investor-conference [SID1234607752]). Those looking to meet with Privo can schedule a meeting through the BIO One-on-One Partnering portal.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The presentation will focus on an introduction of the PRV platform technology’s lead assets (PRV111 and PRV211) and their respective upcoming clinical trial designs in oral cavity cancer (carcinoma and situ) and a basket study for all solid tumors. The localized targeted delivery of our nanoparticles allows the PRV platform to deliver high doses of potent chemotherapeutics while avoiding systemic side effects. This makes the platform particularly well suited for its lead indication, oral cavity cancer (OCC), which is a rare and disfiguring disease resulting in a poor quality of life due to the having no alternative treatment method to surgery. OCC is also known to acquire chemo resistance, which our efficacious nanoparticles mitigate. Privo is excited to showcase the potential of the PRV platform, a discovery that can prevent cancer from being a life changing event.
The Company’s presentation will be available on demand on the BIO CEO & Investor Conference website until March 20, 2022.